

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following items, which are listed on the Substitute PTO-1449 form attached hereto as (**Exhibit A**). Copies of items 1-10 are attached hereto as **Exhibits 1-10**, respectively:

1. Extended European Search Report issued August 20, 2007 in connection with European Application No. 07 010 186.0 (**Exhibit 1**);
2. U.S. Patent No. 5,641,754, issued to Iverson on June 24, 1997 (**Exhibit 2**);
3. PCT International Publication No. WO 97/08184, Dana-Farber Cancer Institute, published March 6, 1997 (**Exhibit 3**);
4. Gu, Yansong et al., (1997) "Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination," Proc. Natl. Acad. Sci. USA, 94:15, pgs. 8076-8081 (**Exhibit 4**);
5. Jackson, Stephen, (1997) "DNA-dependent protein kinase," Int. J. Biochem. Cell Biol., 29:7, pgs. 935-938 (**Exhibit 5**);
6. Jin, Shengfang et al., (1998) "Differential etoposide

sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase," Carcinogenesis, 19:6, pgs. 965-971 (**Exhibit 6**);

7. Ouyang, Honghai et al., (1997) "Ku70 is required for DNA repair but not for T Cell antigen receptor gene recombination in vivo," J. Exp. Med, 186:6, pgs. 921-929 (**Exhibit 7**);
8. Shen, Hongxie et al., (1998) "Increased expression of DNA-dependent protein kinase confers resistance to adriamycin," Biochemica et Biophysica Acta, 1381:2, pgs. 131-138 (**Exhibit 8**);
9. Tseng, B.Y. et al., (1994) "Antisense oligonucleotide technology in the development of cancer therapeutics," Cancer Gene Therapy, 1:1, pgs. 65-71 (**Exhibit 9**);
10. Uhlmann, Eugen et al., (1990) "Antisense oligonucleotides: a new therapeutic principle," Chemical Reviews, 90:4, pgs. 543-584 (**Exhibit 10**);
11. Office Action issued October 12, 2007 in connection with related U.S. Serial No. 09/750,410 (**Exhibit 11**).

Items 2-10 were cited in an Extended European Search Report issued August 20, 2007 by the European Patent Office in connection with related European Patent Application No. 07010186.0. A copy of the Search Report is attached hereto as

Applicants: Gloria C. Li et al.
Serial No.: 10/712,642
Filed: November 12, 2003
Page 14

Exhibit 1. Item 11 is an Office Action issued October 12, 2007 by the U.S. Patent and Trademark Office in connection with a related U.S. Serial No. 09/750,410, filed December 28, 2000.

The Examiner is respectfully requested to make these items of record in the present application by initialing and returning a copy of the enclosed substitute Form PTO 1449.

Pursuant to 37 C.F.R. §1.97(b)(4), no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement.


Applicants: Gloria C. Li et al.
Serial No.: 10/712,642
Filed: November 12, 2003
Page 15

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

No fee, other than the enclosed total fee of \$865.00, including a \$405.00 RCE fee and a \$460.00 fee for a two-month extension of time, is deemed necessary in connection with the filing of this response. However, if any additional fee is required, authorization is given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.	
 John P. White	10/31/07 Date
Reg. No. 28,678	

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

EXHIBIT A